Lonza exits both softgels and liquid-filled hard capsules and NextPharma plans to broaden its technology offering into lipid based finished dosage forms.
Lonza and NextPharma have formed an agreement for the potential sale of Lonza's Ploermel, France and Edinburgh, UK sites, subject to relevant conditions and regulatory approvals.